PubMed Health⌕ Search

Biomedical subjects

Radu Tutuian

Publications and source records attributed to Radu Tutuian.

At least 19 recordsLinked to original sources

Technology review: Esophageal impedance monitoring.

Intraluminal impedance monitoring is a new technique that can be used to detect the flow of liquids and gas through hollow viscera. In combination with manometry, it is used for esophageal function testing and while manometry provides information on contractile activity, impedance provides information on esophageal bolus transit. This is especially useful in patients with nonobstructive dysphagia. However, impedance monitoring appears to be less suitable for the evaluation of patients with achalasia. When used in combination with esophageal pH monitoring, impedance monitoring makes gastroesophageal reflux monitoring more complete because it allows recognition of both acidic and weakly acidic reflux episodes. The results of several studies suggest that impedance-pH monitoring is useful in the evaluation of patients with PPI-resistant typical reflux symptoms, chronic unexplained cough, excessive belching, and rumination.

Electric Impedance↗

Esophageal motility disorders (distal esophageal spasm, nutcracker esophagus, and hypertensive lower esophageal sphincter): modern management.

The group of hypercontractile esophageal motility disorders includes distal esophageal spasm (DES), nutcracker esophagus (NE), and hypertensive lower esophageal sphincter (LES). The clinical relevance of these abnormalities identified during esophageal manometry is debated, and their management can be challenging. Hypercontractile esophageal motility abnormalities are defined through specific manometric criteria. Current pathophysiologic concepts for these abnormalities include defects in the nitronergic neural pathways and imbalances between the cholinergic and nitronergic pathway. Proposed treatments for NE, DES, and hypertensive LES include proton-pump inhibitors, nitrates, calcium channel blockers, phosphodiasterase inhibitors, and tricyclic antidepressants or serotonin reuptake inhibitors. Small case series reported benefits after botulinum toxin injections, dilatations, and myotomies. The optional management of esophageal spasm, NE, and hypertensive LES is still debated. Treatment recommendations are based on controlled studies with small numbers of patients or on case series. Medical treatment, including acid suppression, smooth muscle relaxants, and visceral analgesics, should be tried first. In nonresponding patients, botulinum toxin injections or balloon dilatations can be tried. Pneumatic dilatations or myotomies should be regarded as last-option treatments for nonresponding patients.

Journal Article↗

Intragastric acidity after switching from 5-day treatment with intravenous pantoprazole 40 mg/d to 5-day treatment with oral esomeprazole 40 mg/d or pantoprazole 40 mg/d: an open-label crossover study in healthy adult volunteers.

BACKGROUND: After a course of IV proton pump inhibitor therapy, patients might require continued oral antisecretory therapy. A direct comparison of therapeutic alternatives could assist physicians in decisions regarding optimal acid-suppressive therapy. Oral esomeprazole might control intragastric acidity more effectively compared with other acid-suppressive agents after IV therapy. OBJECTIVE: The aim of this study was to compare intragastric acid control on day 5 of administration of esomeprazole magnesium versus pantoprazole 40 mg PO QD after switching from 5 days of treatment with pantoprazole 40 mg IV in healthy volunteers. METHODS: This randomized, open-label, comparative, 2-way crossover study was conducted at the Oklahoma Foundation for Digestive Research, Oklahoma City, Oklahoma, between October and December 2004. Healthy, Helicobacter pylori-negative adults were randomly assigned to 1 of 2 dosing sequences: pantoprazole IV followed by esomeprazole PO or pantoprazole IV followed by pantoprazole PO. All study medications were administered for 5 days at a dose of 40 mg QD. IV pantoprazole was administered over 2 minutes; all medications were administered 30 minutes before breakfast. There was a 10- to 21-day washout period between each 10-day dosing period. All doses were administered at the study site. Before oral study drug administration on days 1 and 5, 24-hour pH monitoring was performed using a pH catheter positioned 10 cm distal to the lower esophageal sphincter in the stomach. The primary end point was percentage of time with pH >4 (%t pH >4) during the 24-hour pH-monitoring period. Tolerability was assessed using spontaneous reporting, laboratory analysis, and vital-sign measurement. RESULTS: Of 42 subjects randomized to treatment sequences, 4 were withdrawn during the study because of invalid pH data; 38 subjects (24 men, 14 women; mean [SD] age, 25.2 [8.1] years) had assessable data. Day-5 %t pH >4 was 68.5% with esomeprazole and 53.3% with pantoprazole (P < 0.001). Day-1 %t pH >4 was 62.5% with esomeprazole and 51.0% with pantoprazole (P < 0.001). The most common adverse events were rhinitis (2 subjects each with pantoprazole IV and PO; 1 subject with esomeprazole) and headache (2 subjects with esomeprazole; 1 subject with pantoprazole IV). CONCLUSIONS: The results of this study in healthy adult volunteers suggest that switching from pantoprazole 40 mg IV to esomeprazole 40 mg PO QD more effectively suppresses intragastric acid compared with switching from pantoprazole 40 mg IV to pantoprazole 40 mg PO QD. All 3 treatments were well tolerated.

2-Pyridinylmethylsulfinylbenzimidazoles↗

Clinical relevance of the nutcracker esophagus: suggested revision of criteria for diagnosis.

BACKGROUND: Nutcracker esophagus (NE) is a manometric finding defined by peristaltic contractions with a mean distal esophageal amplitude (DEA) >180 mm Hg. This threshold has been selected as it exceeds the average DEA in healthy volunteers by 2 SDs. Since its introduction the clinical significance of this finding has been challenged, as many patients with NE are asymptomatic. AIM: To evaluate whether defining NE based on a different DEA threshold would be clinically more meaningful. METHODS: Retrospective review of prospectively collected manometry data between October 2001 and December 2003. Using previously published normal DEA values (mean and SD) patients with NE were stratified into 3 groups: group A (2 to 3 SD above mean): DEA 180 to 220 mm Hg; group B (3 to 4 SD above mean): DEA 220 to 260 mm Hg; and group C (>4 SD above mean): DEA >260 mm Hg. Symptoms, esophageal acid exposure, bolus transit data, and lower esophageal sphincter data were reviewed. RESULTS: The stratification of 56 NE patients into groups A, B, and C were 31, 16, and 9, respectively. The proportion of patients presenting with chest pain increased from 23% in group A to 69% in group B and 100% in group C. Patients in group C had significantly (P<0.05) higher mean lower esophageal sphincter pressure, shorter bolus transit time, and lower frequency of abnormal reflux. CONCLUSIONS: A revised definition of NE to include patients with a DEA >260 mm Hg, and possibly those with >220 may have greater clinical relevance.

Adolescent↗

Comparison between the combined analysis and the DeMeester Score to predict response to PPI therapy.

BACKGROUND: Distal esophageal acid exposure can be quantified using the DeMeester score (DS) or percentage time pH<4. In addition to these parameters, symptom index (SI) is used to evaluate the association of symptoms and acid reflux. Combined analysis (CA) including the SI and percentage time pH<4 provides a more comprehensive interpretation of pH monitoring results. AIM: To assess whether using CA compared with DS is more accurate for interpretation of pH monitoring. METHOD: pH studies from 450 patients (303 female; mean age 53; range 11 to 88) off therapy between July 2002 and October 2004 were analyzed. DS (normal<14.7), percentage time pH<4 (normal; upright<6.3%, recumbent<1.2%), and the SI (positive symptom if >/=50%) were calculated for each patient. Symptom responses to proton pump inhibitors (PPIs) were assessed in patients with discordant DS and CA. RESULTS: Sixty-six patients were identified as having a normal DS and an abnormal CA. Forty-one (62%) patients had abnormal reflux according to the CA and 25 (38%) had normal reflux but a positive SI. Ten patients were lost to follow-up, 43 (84%) improved on and were currently taking a PPI and 8 (16%) found no benefit from taking a PPI. Five (9%) patients were never tried on a PPI and 3 were still symptomatic. Twenty-two (88%) patients with a positive SI and normal reflux were followed-up (3 never prescribed PPI) and 17 (90%) improved with a PPI. CONCLUSIONS: Interpreting the results of pH monitoring based solely on the composition DS misses patients with an acid "sensitive esophagus," a group of patients who benefit from PPI therapy.

Adolescent↗

Symptom and function heterogenicity among patients with distal esophageal spasm: studies using combined impedance-manometry.

BACKGROUND: Combined multichannel intraluminal impedance and esophageal manometry (MII-EM) is a clinically available tool that assesses the functional defect of various manometric abnormalities. The aim of our study was to evaluate esophageal bolus transit in patients with manometrically defined distal esophageal spasm (DES). METHODS: Patients referred for esophageal function testing underwent combined MII-EM studies including 10 liquid and 10 viscous swallows. Individual swallows were classified using previously published manometric and impedance criteria. DES is traditionally defined as > or =20% simultaneous contractions in the distal esophagus. Diagnosis of esophageal transit abnormalities was defined by the presence of > or =30% incomplete liquid or > or =40% incomplete viscous swallows. RESULTS: Data from 71 patients (43 female, mean age 57 yr, range 16-85) with a manometric diagnosis of DES were analyzed. During liquid swallows, patients with chest pain had higher (p < 0.05) distal esophageal amplitudes (202.3 +/- 34.5 mmHg) and a higher (p < 0.05) percentage of swallows with complete bolus transit (89%+/- 3%) compared to patients presenting with dysphagia (amplitude 117.8 +/- 8.7 mmHg; percentage of complete transit 69%+/- 5%) and patients with reflux symptoms (amplitude 116.4 +/- 12.7 mmHg; percentage of complete transit 74%+/- 5%). Fifty-one percent of the DES patients had a normal bolus transit for liquid and viscous, 24% abnormal bolus transit for one substance, and 25% abnormal bolus transit for liquid and viscous. CONCLUSION: Pressure and bolus transit information in patients with manometrically defined DES points toward heterogenicity of this group of patients. Outcomes data are warranted to evaluate whether stratifying DES patients based on pressure and bolus transit information may improve the clinical approach.

Adolescent↗

Nonacid reflux in patients with chronic cough on acid-suppressive therapy.

BACKGROUND: It is generally accepted that extraesophageal gastroesophageal reflux disease (GERD) symptoms and their persistence despite acid-suppressive therapy are poor prognostic factors for antireflux surgery. Recent studies indicating that cough can be temporally associated with reflux episodes of pH 4 to 7 (ie, nonacid reflux) reinvigorates the need for a more careful workup in patients with cough suspected to be due to GERD. AIM: To evaluate the frequency of chronic cough associated with nonacid reflux and the response of these patients to laparoscopic Nissen fundoplication. METHODS: We retrospectively reviewed data from patients with persistent cough despite twice-daily proton pump inhibitor (PPI) with or without the use of nighttime regimens of histamine-2 receptor antagonist (H2RA), who had undergone combined multichannel intraluminal impedance and pH monitoring. The association of cough and reflux was evaluated by calculating the symptom index (SI) [positive if > or = 50%]. A subset of patients with positive SI values for impedance-detected reflux with therapy was referred for laparoscopic Nissen fundoplication. RESULTS: Of 50 patients (38 female patients; mean age, 43 years; age range, 6 months to 84 years) who were monitored while receiving therapy, 13 patients (26%) had a positive SI for cough. The SI-positive group had a lower percentage of female patients and patients of younger age compared to the SI-negative group. Laparoscopic Nissen fundoplication was performed in six SI-positive patients who became asymptomatic and stopped receiving acid-suppressive therapy during follow-up evaluations (median time, 17 months; range, 12 to 27 months). CONCLUSION: Impedance pH monitoring should be performed while receiving therapy in patients with persistent symptoms who are receiving PPI therapy. A positive SI for nonacid reflux may be helpful in selecting patients who will benefit from antireflux surgery.

Adolescent↗

Update in the diagnosis of gastroesophageal reflux disease.

Clinical manifestations of gastroesophageal reflux disease (GERD) include heartburn, regurgitation, dysphagia, chest pain, cough and other extraesophageal symptoms. GERD is known to cause erosive esophagitis, Barrett esophagus and has been linked to the development of adenocarcinoma of the esophagus. Currently upper gastrointestinal endoscopy is the main clinical tool for visualizing esophageal lesions. Since the majority of GERD patients do not have endoscopic visible lesions other methods are required to document the abnormal acid exposure in the distal esophagus. For many clinicians ambulatory esophageal pH monitoring is the gold standard in diagnosing GERD since it quantifies distal esophageal acid exposure and allows the evaluation of the relationship between symptoms and acid reflux. The availability of highly selective gastric acid suppressive therapy led to the introduction of short trials of proton pump inhibitors (PPI) to diagnose GERD. PPI trials are often used as a first line diagnostic tool in clinical practice and in particular in the primary care settings. This development has a major influence in the type of patients referred to gastrointestinal specialists, the current trend being that gastroenterologists are asked to evaluate an increasing number of patients with persistent GERD symptoms while on PPI therapy. In these patients the question is whether the persistent symptoms are or not associated with reflux (acid or non-acid). In the recent years combined multichannel intraluminal impedance and pH (MII-pH) monitoring has become a clinical tool that permits the clarification of the mechanisms underlying the persistent symptoms on acid suppressive therapy.

Gastroesophageal Reflux↗

Ingestion of acidic foods mimics gastroesophageal reflux during pH monitoring.

Ingestion of acidic foods may produce artifactual drops in pH to < 4 that may be difficult to differentiate from a true acid reflux event. We aimed to evaluate intraesophageal pH changes during the ingestion of acidic food and describe the frequency and implications of acidic food ingestion on ambulatory pH monitoring. Ten normal volunteers (six females; mean age, 34) underwent combined impedance-pH testing with a pH electrode placed 5 cm above the lower esophageal sphincter. Each volunteer received 50 ml each of acidic foods in random order. Nadir and mean pH for 30 sec after ingestion of each substance were recorded. Subsequently 100 randomly selected reflux monitor diaries were reviewed, searching for ingestion of acidic foods, and 100 pH tracings were reviewed to evaluate the impact of including/excluding meal periods on percentage time pH < 4 and DeMeester scores. All foods produced abrupt drops to pH < 4, in 80% of cases exceeding 30 sec. During ambulatory pH monitoring 78% of patients recorded ingestion of at least 1 of the 10 tested substances during meals, the majority admitting ingesting carbonated beverages. Not excluding meal periods would have led to the misinterpretation of 6-16% of tracings, depending on the criteria used to identify abnormal acid exposure. We conclude that ingestion of acidic foods is frequent and carries the risk of overdiagnosing GERD. Current findings support the recommendations to carefully instruct patients to record all oral intake and to exclude meal periods from the analysis.

Adult↗

Esophageal function testing: role of combined multichannel intraluminal impedance and manometry.

Combined multichannel intraluminal impedance and manometry (MII-EM) is a relatively new technique that allows simultaneous measurement of intraesophageal pressures and bolus transit. Combined MII-EM has the ability to identify what percentage of manometric normal/peristaltic, ineffective, and simultaneous swallows have complete or incomplete bolus transit. Predictors of normal bolus transit in patients with ineffective esophageal motility are the distal esophageal amplitude, the number of sites with low amplitudes, and the overall number of manometric ineffective contractions. Outcome studies are necessary to evaluate whether combined MII-EM is superior to traditional manometry in evaluating patients with nonobstructive dysphagia and in identifying patients at risk for developing dysphagia after antireflux surgery.

Deglutition Disorders↗

Reflux monitoring: role of combined multichannel intraluminal impedance and pH.

Combined multichannel intraluminal impedance and pH (MII-pH) is a promising technique that identifies liquid, gas, and mixed gastroesophageal reflux and categorizes it into acid and nonacid types. Gastroesophageal monitoring using combined MII-pH reconfirms previously reported data that there is a difference between refluxate volume presence time in the esophagus and time pH less than 4. Only one in five patients with persistent symptoms on acid-suppressive therapy have symptoms associated with persistent acid reflux, whereas two of five patients have symptoms associated with nonacid reflux; the remaining patients do not have any type of GER related to their symptoms. Combined MII-pH is a useful tool in evaluating patients with persistent symptoms on acid-suppressive therapy, patients with atypical symptoms, and infants.

Electric Impedance↗

Multichannel intraluminal impedance: general principles and technical issues.

Multichannel intraluminal impedance (MII) is a new technology that allows detection of bolus movement without the use of external radiation or radiolabeled substances. The principles of MII are based on changes in resistance to alternating electrical current (impedance) induced by the presence of various boluses within the esophagus. The timing of changes in multiple impedance-measuring segments in the esophagus allows determination of the direction of bolus movement. Combined MII and manometry (MII-EM) provides simultaneous information on intraesophageal pressures and bolus transit, offers the ability to monitor all types of reflux, and allows the detection of the physical (liquid, gas, or mixed) and chemical (acid, nonacid) characteristics of the gastroesophageal refluxate.

Electric Impedance↗